TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
OncoSil Medical Ltd ( (AU:OSL) ) has provided an announcement.
OncoSil Medical Limited announced a change in the director’s interest, with Lelde Smits acquiring 41,067 shares in lieu of cash director fees for the period from October 2025 to September 2026. This move, approved by shareholders at the 2025 Annual General Meeting, reflects the company’s strategic approach to align director incentives with company performance, potentially impacting stakeholder confidence and the company’s market positioning.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited operates in the medical technology industry, focusing on the development and commercialization of innovative medical devices. The company’s primary product is a targeted radioactive implant for the treatment of pancreatic cancer, aiming to improve patient outcomes and provide new treatment options in oncology.
Average Trading Volume: 26,084
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$20.15M
Learn more about OSL stock on TipRanks’ Stock Analysis page.